

Special Issue

Immunization and Immunotherapy against Emerging Infectious Diseases: Current Challenges, Innovative Vaccine Development and Vaccine Adjuvant Technologies

Message from the Guest Editors

Newly emerging and reemerging infectious pathogens, especially the unprecedented viral epidemics and pandemics, have threatened animals and humans. Several interlaced and synergistic factors could accelerate the emergence and spread of these life-threatening pathogens in hosts such as animal and/or human populations. Due to the limited antimicrobial options against emerging and reemerging infectious pathogens and the rapid development of drug-resistant strains following uncontrolled implementation of these medications to infected animals, the vaccination and cell-based immunostimulatory therapies remain pivotal options against these infectious pathogens in both animal and human populations. Therefore, in this issue, we are interested in receiving manuscripts for studies with innovative findings in the following topics:

- Immunization against emerging infectious diseases;
- Immunotherapy against emerging infectious diseases;
- Challenges to current vaccination strategies;
- Innovative vaccine development (new-generation) technologies;
- Novel vaccine adjuvant technologies.

Guest Editors

Dr. Ahmed Mostafa

Center of Scientific Excellence for Influenza Viruses, National Research Centre, 12622 Giza, Egypt

Dr. Mobarak Abu Mraheil

Giessen Institute for Medical Microbiology, Justus-Liebig University, 35392 Giessen, Germany

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/153105

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).